Arvinas Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. | Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. | NextCure NextCure is a biopharmaceutical company focused on discovering and developing next-generation immuno-oncology-based drugs. | |||
Founding Date | Founding Date N/A | Founding Date 2018 | Founding Date 2016 | Founding Date 2015 | Founding Date 2017 |
Type | Type Public | Type Public | Type Public | Type Public | Type Private |
Tags | |||||
Locations | Locations New Haven, US HQ | Locations South San Francisco, US HQ Bothell, US Seattle, US | Locations Cambridge, US HQ Cambridge, US | Locations Beltsville, US HQ | Locations New York, US HQ |
Employees | Employees 13329% increase | Employees 188 | Employees 16135% increase | Employees N/A | Employees 3 |
Valuation ($) | Valuation ($) 1.9 b | Valuation ($) 243.3 m | Valuation ($) 452 m | Valuation ($) 39.2 m | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $78.5m (FY, 2023) | Revenue (est.) $130k (FY, 2023) | Revenue (est.) $34.2m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A |
Net income | Net income ($367.3m) (FY, 2023) | Net income ($234.6m) (FY, 2023) | Net income ($98.4m) (FY, 2023) | Net income ($62.7m) (FY, 2023) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised $ 111.6m | Total funding raised N/A | Total funding raised $ 50m | Total funding raised $ 160m | Total funding raised $ 43m |